Page 142 - RusRPTOct22

waste and the risk of nuclear accidents is far too significant to ignore,” said Ariadna Rodrigo, EU sustainable finance campaigner at Greenpeace. “This fake green label is incompatible with EU environment and climate laws.” The complaint is that channelling money to gas projects -- albeit with strict conditions attached -- is not compatible with the EU’s climate neutrality goal, which is enshrined into law, and the Paris Agreement. The NGOs argue that it will take money away from renewable sources of electricity like wind and solar. Greenpeace highlighted the waste from nuclear power, as well as the long-time to construct new facilities.
Electricity in Eastern Europe costs 6 times more than in Ukraine. The exchange price for electricity in the Eastern European countries on September 6 was €480 per MWh. (UAH 17.50/kWh). This is six times higher than the price in Ukraine, the Market Operator reported. Thus, in Hungary on September 6, the wholesale price of electricity was €484 per MWh, in Slovakia – €483 per MWh, in the Czech Republic – €474 per MWh. In Ukraine, the exchange price remains at UAH 3.1/kWh. or €85 per MWh.
9.1.11 Metallurgy & mining sector news
Russian gems are hard to sell following the invasion of Ukraine and after mining giant Alrosa PJSC was hit with US sanctions. But there’s a handful of Indian and Belgian buyers who are snapping up large volumes at lucrative terms, getting to pick and choose the diamonds they need while others stay away. The deals are happening quietly, even for the famously secretive diamond world. And while they’re not breaching sanctions, there are other risks to consider — heavyweights like Tiffany & Co. and Signet Jewelers Ltd. don’t want Russian diamonds that were mined since the war began, and suppliers say they are worried about losing crucial contracts by dealing in Alrosa gems.
9.1.13 Other sector news
Approximately 300 drugs developed by international pharmaceutical companies will not enter the Russian market in the next 10 years due to the fact that sanctions have stopped clinical trials in Russia, Kommersant writes.
The publication refers to the calculations of the Center for Mathematical Modeling in Drug Development of the First Moscow State Medical University. Sechenov. The math is simple: The researchers selected 6,000 promising drugs from the top 20 drug companies at any stage of trial and applied a typical 5% to 10% market launch rate to them.
Clinical trials in Russia were stopped by all foreign companies by June of this year, citing the impossibility of guaranteeing the delivery of biological samples
142 RUSSIA Country Report October 2022 www.intellinews.com